The House Energy and Commerce Health Subcommittee today held a hearing titled “Combatting an Epidemic: Legislation to Help Patients with Substance Use Disorders.” 

Witnesses included officials from the Department of Health and Human Services and the Drug Enforcement Administration. Subcommittee members inquired about the status of several not yet implemented provisions of the 21st Century Cures Act and Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act. They also discussed 14 bills to further expand access to substance use disorder treatment, including two bipartisan bills supported by the AHA. 

The Opioid Workforce Act (H.R. 3414/S.2892) would add 1,000 Medicare-funded training positions to approved residency programs in addiction medicine, addiction psychiatry or pain management over a five-year period. The Ways and Means Committee, which also has jurisdiction over the bill, reported it favorably last June.

The Mainstreaming Addiction Treatment Act (H.R. 2482/S. 2074) would eliminate a requirement that practitioners apply for a separate waiver from the Drug Enforcement Administration to prescribe buprenorphine for SUD treatment. 
 

Headline
The Food and Drug Administration today announced it is accelerating regulatory action on a new class of psychedelic-based therapies, following an April 18…
Headline
Americans across 43 states enrolled in health plans from the nation’s four largest commercial health insurers face potential disparities in finding in-network…
Headline
David Stark, chief of government and external affairs and philanthropy officer at UnityPoint Health, shares how a major philanthropic investment is helping…
Headline
The Substance Abuse and Mental Health Services Administration has released an advisory examining innovative solutions to close gaps in behavioral health care…
Headline
The cigarette smoking rate among U.S. adults dropped to 9.9% in 2024, the lowest level ever recorded, according to a report by the New England Journal of…
Headline
A study published by BMJ found that glucagon-like peptide-1 (GLP-1) drugs could help reduce the risk of various substance use disorders, including for alcohol…